Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt No Debt
AVXS's Cash-to-Debt is ranked higher than
62% of the 864 Companies
in the Global Biotechnology industry.

( Industry Median: 53.59 vs. AVXS: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
AVXS' s Cash-to-Debt Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 4
Altman Z-Score: 53.54
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE % -48.76
AVXS's ROE % is ranked lower than
56% of the 773 Companies
in the Global Biotechnology industry.

( Industry Median: -39.29 vs. AVXS: -48.76 )
Ranked among companies with meaningful ROE % only.
AVXS' s ROE % Range Over the Past 10 Years
Min: -140.56  Med: -97.65 Max: -48.76
Current: -48.76
-140.56
-48.76
ROA % -45.13
AVXS's ROA % is ranked lower than
59% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. AVXS: -45.13 )
Ranked among companies with meaningful ROA % only.
AVXS' s ROA % Range Over the Past 10 Years
Min: -807.09  Med: -243.88 Max: -45.13
Current: -45.13
-807.09
-45.13
ROC (Joel Greenblatt) % -751.42
AVXS's ROC (Joel Greenblatt) % is ranked lower than
57% of the 827 Companies
in the Global Biotechnology industry.

( Industry Median: -476.30 vs. AVXS: -751.42 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
AVXS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -109850  Med: -66010.99 Max: -682.69
Current: -751.42
-109850
-682.69
GuruFocus has detected 1 Warning Sign with AveXis Inc $AVXS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» AVXS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

AVXS Guru Trades in Q1 2016

Paul Tudor Jones 14,250 sh (New)
» More
Q2 2016

AVXS Guru Trades in Q2 2016

Jim Simons 5,831 sh (New)
Paul Tudor Jones Sold Out
» More
Q3 2016

AVXS Guru Trades in Q3 2016

Paul Tudor Jones 13,500 sh (New)
Jim Simons 53,900 sh (+824.37%)
» More
Q4 2016

AVXS Guru Trades in Q4 2016

Steven Cohen 540,400 sh (New)
Paul Tudor Jones Sold Out
Jim Simons 42,300 sh (-21.52%)
» More
» Details

Insider Trades

Latest Guru Trades with AVXS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:JUNO, OTCPK:ABCZY, NAS:PTLA, NAS:LGND, NAS:PRTA, NYSE:XON, NAS:SAGE, NAS:AGIO, NAS:TBPH, NAS:HALO, OTCPK:DBVTF, NYSE:CBM, NAS:GBT, NAS:AAAP, OTCPK:MPSYY, NAS:ONCE, NAS:SRPT, NAS:ARRY, NAS:FGEN, OTCPK:SOLTF » details
Traded in other countries:AX4.Germany,
AveXis Inc is a clinical-stage gene therapy company. It is engaged in developing and commercializing novel treatments for patients suffering from rare and life-threatening neurological genetic diseases. Its product candidate is AVXS-101.

AveXis Inc was formed on March 8, 2010 in the state of Delaware as BioLife Cell Bank, LLC. In January 2012, the Company converted from a limited liability company to a corporation, BioLife Cell Bank, Inc. In January 2014, the Company amended and restated its Certificate of Incorporation to change its name to AveXis, Inc. It is a clinical-stage gene therapy company. The Company is engaged in developing and commercializing novel treatments for patients suffering from rare and life-threatening neurological genetic diseases. Its product candidate, AVXS-101, is a gene therapy product candidate currently in a Phase 1 clinical trial for the treatment of spinal muscular atrophy, or SMA, Type 1, the genetic cause of infant mortality. The Company manages its operations as a single segment, which is developing and commercializing gene therapy treatments for patients suffering from rare and life-threatening neurological genetic diseases. The Company competes with pharmaceutical and biotechnology companies, academic research institutions, government agencies and public and private research institutions.

Ratios

vs
industry
vs
history
PB Ratio 8.34
AVXS's PB Ratio is ranked lower than
77% of the 1091 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. AVXS: 8.34 )
Ranked among companies with meaningful PB Ratio only.
AVXS' s PB Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 8.97
Current: 8.34
0
8.97
Current Ratio 10.03
AVXS's Current Ratio is ranked higher than
80% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. AVXS: 10.03 )
Ranked among companies with meaningful Current Ratio only.
AVXS' s Current Ratio Range Over the Past 10 Years
Min: 0.35  Med: 4.9 Max: 10.03
Current: 10.03
0.35
10.03
Quick Ratio 10.03
AVXS's Quick Ratio is ranked higher than
80% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. AVXS: 10.03 )
Ranked among companies with meaningful Quick Ratio only.
AVXS' s Quick Ratio Range Over the Past 10 Years
Min: 0.35  Med: 4.9 Max: 10.03
Current: 10.03
0.35
10.03

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 9.49
AVXS's Price-to-Net-Cash is ranked lower than
64% of the 739 Companies
in the Global Biotechnology industry.

( Industry Median: 6.36 vs. AVXS: 9.49 )
Ranked among companies with meaningful Price-to-Net-Cash only.
AVXS' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0  Med: 0 Max: 9.97
Current: 9.49
0
9.97
Price-to-Net-Current-Asset-Value 9.28
AVXS's Price-to-Net-Current-Asset-Value is ranked lower than
68% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: 5.79 vs. AVXS: 9.28 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
AVXS' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0  Med: 0 Max: 9.75
Current: 9.28
0
9.75
Price-to-Tangible-Book 8.32
AVXS's Price-to-Tangible-Book is ranked lower than
72% of the 1017 Companies
in the Global Biotechnology industry.

( Industry Median: 4.44 vs. AVXS: 8.32 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
AVXS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0  Med: 0 Max: 8.97
Current: 8.32
0
8.97
Earnings Yield (Greenblatt) % -4.62
AVXS's Earnings Yield (Greenblatt) % is ranked higher than
61% of the 1273 Companies
in the Global Biotechnology industry.

( Industry Median: -8.24 vs. AVXS: -4.62 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
AVXS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -1680.15  Med: 0 Max: 0
Current: -4.62
-1680.15
0

More Statistics

EPS (TTM) $ -3.71
Short Percentage of Float20.18%
52-Week Range $20.51 - 85.98
Shares Outstanding (Mil)27.74

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)